Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,168.00 at Guggenheim

Eli Lilly and Company (NYSE:LLY) had its price target boosted by Guggenheim from $1,161.00 to $1,168.00 in a research report report published on Thursday,MarketScreener reports. They currently have a buy rating on the stock.

Several other analysts have also commented on the stock. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Barclays assumed coverage on Eli Lilly and Company in a research report on Thursday, February 19th. They set an “overweight” rating and a $1,350.00 target price on the stock. Daiwa Securities Group upped their price target on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Morgan Stanley increased their price target on Eli Lilly and Company from $1,290.00 to $1,313.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Finally, Loop Capital set a $1,200.00 target price on Eli Lilly and Company in a research note on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $1,229.59.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,022.16 on Thursday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The stock has a market cap of $964.26 billion, a PE ratio of 44.54, a price-to-earnings-growth ratio of 1.20 and a beta of 0.39. The business has a 50-day simple moving average of $1,053.57 and a 200-day simple moving average of $925.14.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period last year, the company earned $5.32 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is presently 30.15%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Maryland Capital Advisors Inc. acquired a new stake in Eli Lilly and Company in the 4th quarter valued at about $25,000. Sumitomo Mitsui Financial Group Inc. purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $27,000. Vermillion & White Wealth Management Group LLC increased its holdings in shares of Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after purchasing an additional 16 shares during the last quarter. Evolution Wealth Management Inc. purchased a new position in Eli Lilly and Company during the second quarter worth approximately $29,000. Finally, Steph & Co. boosted its stake in Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after buying an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Head‑to‑head Phase 3 data show oral GLP‑1 candidate orforglipron delivered superior A1C reduction and greater weight loss vs. oral semaglutide; Lilly has submitted orforglipron widely and is eyeing potential U.S. action in Q2 — a major fundamental catalyst for LLY. Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
• Positive Sentiment: Analysts and media are lifting sentiment: RBC started coverage at “Outperform” with a $1,250 PT and Guggenheim nudged its target higher — these institutional signals support upside expectations. RBC Capital Starts Eli Lilly (LLY) at Outperform Guggenheim adjusts price target on Eli Lilly to $1,168
• Positive Sentiment: High‑profile media support: Jim Cramer publicly favored Eli Lilly over Novo Nordisk, which can amplify retail and momentum flows into LLY. Jim Cramer Recommends Eli Lilly over Novo Nordisk
• Positive Sentiment: Capacity and R&D investments: building permits for a $77M expansion in Concord and deployment of the LillyPod supercomputer at HQ signal expanded manufacturing and AI/R&D capability to support scale-up if demand accelerates. Eli Lilly plans $77M expansion of manufacturing campus in Concord Eli Lilly begins using ‘LillyPod’ supercomputer at Indy HQ
• Neutral Sentiment: Partnership and practice initiatives (OTF/OMA collaboration) expand clinician adoption pathways for obesity care but are longer‑term adoption plays rather than immediate revenue drivers. OTF + Lilly Collaboration Update on Registration Response | OMA QI Scaling Initiative Gains National Response
• Neutral Sentiment: Competitive landscape: smaller rivals like Viking and other oral programs keep the market dynamic, but most are earlier‑stage — worth monitoring as potential future threats or M&A targets rather than immediate disrupters. Viking Therapeutics: The High-Stakes Weight Loss Contender (LLY)
• Negative Sentiment: Novo Nordisk’s recent GLP‑1 list‑price cuts and broader pricing scrutiny create concerns about margin and pricing dynamics in the obesity/GLP‑1 market — this is a principal reason for near‑term volatility and contributed to recent intraday weakness in LLY. Eli Lilly stock down: Novo cut GLP‑1 prices

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.